hotspot -WSS

hotspot

author：explore 2025-09-03 03:28:09 - browse：931

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： European regulators recommend Amylyx's ALS drug be rejected

Wikipedia

WSS

STAT Readout Newsletter: Today in biotech, life science news

Vertex non

Readout LOUD podcast: Merger Mondays, Ozempic panic

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Life sciences deals on track to hit lowest point since 2017

Novo Nordisk to expand supply of Wegovy for U.S. patients

hotspot

hotspot

leisure time

Continuity nursing helped my family in our darkest PICU moments

Covid misinformation case heads to Supreme Court

Medicare proposal to cover medical devices draws a mixed reaction

Woodcock on FDA’s accelerated approval and her next chapter

DIEP, the 'gold standard' of breast reconstruction, is under threat

Female surgeons have lower rates of long

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare drug price negotiation’s day in court

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cognito secures funding to test medical device for Alzheimer's

entertainment

A $475,000 price tag for a new cancer drug: crazy or meh?

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Peter Marks talks Operation Warp Speed for Rare Diseases

Eight reasons why you should get an updated Covid vaccine

What we need to know about Arena Bioworks

focus

entertainment

Wikipedia

focus